Novartis CF drug delivery device gets provisional NICE "yes"
This article was originally published in Clinica
Executive Summary
Novartis’s cystic fibrosis (CF) therapy device for inhaled delivery of tobramycin, the TOBI Podhaler, yesterday received a preliminary recommendation from the UK’s NICE.